Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial

Stuart SchlossmanMS Research Study and Reports

By RTT News,  
Drugmaker Biogen Idec ( BIIB ) Thursday announced top-line results from the Phase 2 acute optic neuritis or AON RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system.

Anti-LINGO-1 demonstrated an improvement in the study’s primary endpoint, recovery of optic nerve latency, relative to placebo. The study showed no effect on secondary endpoints, including change in thickness of the retinal layers and visual function.

AON damages the optic nerve, causing loss of the myelin sheath and axonal injury, and may result in loss of visual function. It is considered a good clinical model to measure the hypothesized mechanisms of action of anti-LINGO-1, remyelination and neuroprotection.

Read more 



Or read another article here: Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis …

~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT with MS Views and News – OPT-IN here

.
.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews